End-of-day quote
Shenzhen S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
7.97
CNY
|
-1.97%
|
|
+1.14%
|
-10.15%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,789
|
3,648
|
3,989
|
9,184
|
9,835
|
7,222
|
Enterprise Value (EV)
1 |
4,991
|
3,822
|
3,590
|
8,514
|
8,800
|
6,005
|
P/E ratio
|
20.8
x
|
-9.27
x
|
36
x
|
57.1
x
|
46.3
x
|
29.2
x
|
Yield
|
0.87%
|
-
|
0.84%
|
0.53%
|
0.66%
|
-
|
Capitalization / Revenue
|
3.53
x
|
3.15
x
|
3.11
x
|
6.76
x
|
6.25
x
|
4.78
x
|
EV / Revenue
|
3.68
x
|
3.3
x
|
2.8
x
|
6.27
x
|
5.59
x
|
3.97
x
|
EV / EBITDA
|
13.6
x
|
-90.8
x
|
12.1
x
|
33.1
x
|
27.7
x
|
15.2
x
|
EV / FCF
|
-79.3
x
|
-131
x
|
16.4
x
|
122
x
|
44.3
x
|
42.3
x
|
FCF Yield
|
-1.26%
|
-0.76%
|
6.09%
|
0.82%
|
2.26%
|
2.37%
|
Price to Book
|
2.04
x
|
1.97
x
|
1.89
x
|
4.11
x
|
4.1
x
|
2.95
x
|
Nbr of stocks (in thousands)
|
8,35,724
|
8,14,181
|
8,14,181
|
8,14,181
|
8,14,181
|
8,14,181
|
Reference price
2 |
5.730
|
4.480
|
4.900
|
11.28
|
12.08
|
8.870
|
Announcement Date
|
17/02/19
|
28/04/20
|
26/04/21
|
29/03/22
|
29/03/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,355
|
1,157
|
1,281
|
1,358
|
1,573
|
1,512
|
EBITDA
1 |
367.4
|
-42.08
|
295.8
|
257.4
|
318
|
394.9
|
EBIT
1 |
289.4
|
-122.4
|
213.7
|
156.5
|
211.4
|
310.7
|
Operating Margin
|
21.37%
|
-10.58%
|
16.68%
|
11.53%
|
13.44%
|
20.55%
|
Earnings before Tax (EBT)
1 |
288.5
|
-500.7
|
63.74
|
178.9
|
250.2
|
329.7
|
Net income
1 |
229.7
|
-393.6
|
111
|
160.7
|
212.2
|
247.7
|
Net margin
|
16.95%
|
-34.01%
|
8.66%
|
11.83%
|
13.49%
|
16.38%
|
EPS
2 |
0.2756
|
-0.4835
|
0.1363
|
0.1974
|
0.2607
|
0.3042
|
Free Cash Flow
1 |
-62.95
|
-29.22
|
218.8
|
69.94
|
198.7
|
142.1
|
FCF margin
|
-4.65%
|
-2.53%
|
17.07%
|
5.15%
|
12.63%
|
9.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
73.96%
|
27.17%
|
62.49%
|
35.98%
|
FCF Conversion (Net income)
|
-
|
-
|
197.1%
|
43.52%
|
93.64%
|
57.37%
|
Dividend per Share
2 |
0.0500
|
-
|
0.0410
|
0.0600
|
0.0800
|
-
|
Announcement Date
|
17/02/19
|
28/04/20
|
26/04/21
|
29/03/22
|
29/03/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
203
|
174
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
399
|
670
|
1,036
|
1,217
|
Leverage (Debt/EBITDA)
|
0.5513
x
|
-4.138
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-63
|
-29.2
|
219
|
69.9
|
199
|
142
|
ROE (net income / shareholders' equity)
|
9.74%
|
-21.7%
|
1.21%
|
5.54%
|
8.18%
|
10.2%
|
ROA (Net income/ Total Assets)
|
5.45%
|
-2.41%
|
4.38%
|
3.08%
|
4.23%
|
6.24%
|
Assets
1 |
4,216
|
16,313
|
2,533
|
5,220
|
5,012
|
3,971
|
Book Value Per Share
2 |
2.800
|
2.270
|
2.590
|
2.750
|
2.950
|
3.000
|
Cash Flow per Share
2 |
0.2600
|
0.3700
|
0.7100
|
0.8000
|
1.150
|
1.130
|
Capex
1 |
160
|
255
|
118
|
80.5
|
61.6
|
28.4
|
Capex / Sales
|
11.83%
|
22.06%
|
9.25%
|
5.93%
|
3.92%
|
1.88%
|
Announcement Date
|
17/02/19
|
28/04/20
|
26/04/21
|
29/03/22
|
29/03/23
|
18/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -10.15% | 90Cr | | +30.38% | 68TCr | | +29.82% | 57TCr | | -4.36% | 36TCr | | +19.30% | 33TCr | | +3.73% | 28TCr | | +16.34% | 24TCr | | +8.94% | 21TCr | | -7.61% | 20TCr | | +7.68% | 17TCr |
Other Pharmaceuticals
|